Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
An examination of short-term operating activity ratios reveals several noteworthy trends over the observed period. Generally, the company demonstrates consistent, though fluctuating, efficiency in managing its inventory, receivables, and payables. However, significant shifts in working capital turnover and associated cycle times are apparent, particularly in the later periods.
- Inventory Management
- Inventory turnover exhibits a relatively stable pattern, fluctuating between 3.50 and 4.15. A slight downward trend is visible from early 2022 through the first half of 2023, followed by a recovery towards the end of 2023 and into 2024. The most recent periods show a slight decline again. Correspondingly, the average inventory processing period generally increased from 94 days to 104 days between April 2022 and September 2023, before decreasing to 90 days by December 2025. This suggests a potential slowing in the rate of inventory sales followed by a recent improvement in inventory management.
- Receivables Management
- Receivables turnover shows moderate variability, ranging from approximately 6.09 to 7.15. A dip is observed in late 2022 and early 2023, followed by a rebound. The average receivable collection period remained relatively consistent around 53-55 days for much of the period, with a slight increase to 58 days by December 2025. This indicates a generally stable collection process, though a minor lengthening of the collection cycle is apparent in the most recent quarter.
- Payables Management
- Payables turnover demonstrates a gradual increase from 5.04 to 5.88 between April 2022 and September 2024, indicating an increasing efficiency in paying suppliers. A slight decrease is then observed in the final periods. The average payables payment period correspondingly decreased from 73 days to 60 days before stabilizing around 63-67 days. This suggests the company initially improved its management of payment terms, but has recently maintained a more consistent payment schedule.
- Working Capital & Operating Cycles
- Working capital turnover experienced substantial fluctuations. It declined significantly from 5.91 in April 2022 to 3.08 in June 2023, before a dramatic increase to 8.85 in December 2024. This suggests a significant change in the relationship between working capital and sales, potentially driven by shifts in operational strategy or external factors. The operating cycle mirrored this trend, increasing from 147 days to 163 days and then decreasing to 142 days, before increasing again to 155 days. The cash conversion cycle followed a similar pattern, increasing from 75 days to 98 days and then decreasing to 76 days, before increasing to 92 days. These cycles indicate a lengthening of the time required to convert investments in inventory and receivables into cash, followed by a period of improvement, and then a recent lengthening again. The substantial changes in these metrics warrant further investigation.
In summary, the company generally maintains stable efficiency in its core operating cycles, with some fluctuations. The most significant observation is the substantial volatility in working capital turnover and associated cycle times, particularly in the latter half of the period, which may indicate strategic shifts or responses to changing market conditions.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Inventories | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Inventory turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Inventory turnover exhibited a generally stable pattern over the observed period, with fluctuations occurring throughout the quarters. An initial decline is noted from the first to the second quarter, followed by a period of relative stability before an increase towards the end of 2022. This pattern repeats, with variations, over the subsequent years.
- Overall Trend
- The inventory turnover ratio generally fluctuates between 3.50 and 4.15. While there isn't a strong, consistent upward or downward trend, the ratio demonstrates a tendency to be higher in the fourth quarter of each year, suggesting potentially increased sales or inventory management efforts during that period.
- Short-Term Fluctuations (2022-2023)
- From April 2022 to December 2022, the ratio decreased from 3.87 to 3.71, then recovered to 3.80 by September 2022, before peaking at 4.03 in December 2022. A subsequent decrease to 3.50 was observed in March 2023, followed by a slight recovery to 3.58 in June 2023. This suggests potential seasonal effects or changes in sales velocity during this period.
- Recent Performance (2024-2025)
- The ratio remained relatively stable between 3.59 and 3.80 from March 2024 to September 2024. An increase to 4.15 was observed in December 2024, mirroring the pattern from previous years. This trend continued into 2025, with the ratio fluctuating between 3.60 and 4.04, indicating continued consistency in inventory management practices. The most recent value, as of December 2025, is 4.04, which is consistent with the higher end of the observed range.
- Relationship to Cost of Sales and Inventories
- The fluctuations in inventory turnover appear to correlate with changes in both cost of sales and inventory levels. Periods of increasing cost of sales, coupled with relatively stable or decreasing inventory levels, generally result in higher turnover ratios. Conversely, decreases in cost of sales or increases in inventory levels tend to lower the ratio. The observed pattern suggests a responsive inventory management system that adjusts to changes in demand and sales activity.
In conclusion, the inventory turnover ratio demonstrates a generally healthy and consistent performance, with periodic fluctuations likely driven by seasonal sales patterns and inventory management strategies. The recent trend indicates continued efficient inventory control.
Receivables Turnover
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Trade accounts receivable, less allowance for doubtful accounts | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Receivables turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Trade accounts receivable, less allowance for doubtful accounts
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits fluctuations over the observed period, generally remaining within a relatively narrow range. An initial period of stability is followed by a decline, then a recovery, and a subsequent leveling off with a slight downward trend towards the end of the period.
- Overall Trend
- The receivables turnover ratio begins at 6.87 and demonstrates moderate variability throughout the analyzed timeframe. It generally fluctuates between approximately 6.09 and 7.15. A slight decreasing trend is apparent in the most recent quarters.
- Initial Period (Apr 1, 2022 – Dec 31, 2022)
- The ratio begins at 6.87 and experiences a slight decrease to 6.81, followed by a peak at 7.09. It then declines to 6.40 by the end of 2022, indicating a potential lengthening of the collection period during that final quarter.
- Recovery and Stabilization (Mar 31, 2023 – Dec 31, 2024)
- The ratio recovers to 6.89 in the first quarter of 2023 and remains relatively stable, fluctuating between 6.64 and 7.15 through the end of 2024. This suggests a return to more consistent collection practices. The highest value of 7.15 is observed in June 2024.
- Recent Trend (Mar 29, 2024 – Dec 31, 2025)
- From March 2024 onwards, the ratio exhibits a gradual downward trend, decreasing from 7.02 to 6.28. While the decline is moderate, it warrants monitoring to determine if it signals a sustained increase in the time required to collect receivables. The lowest value of 6.28 is observed in December 2025.
The observed fluctuations in receivables turnover are likely influenced by changes in sales volume, credit policies, and the composition of the customer base. Further investigation into these factors would provide a more comprehensive understanding of the trends.
Payables Turnover
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Trade accounts payable | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Payables turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Trade accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The payables turnover ratio exhibits a generally stable pattern with moderate fluctuations over the observed period. Initial values indicate a ratio around 5.0, followed by a period of increase and subsequent stabilization before a slight decline towards the end of the period.
- Initial Period (Apr 1, 2022 – Dec 31, 2022)
- The payables turnover ratio begins at 5.04 and demonstrates relative stability, fluctuating between 5.00 and 5.61. This suggests consistent management of trade accounts payable in relation to cost of sales during this timeframe. A slight increase is observed from the beginning to the end of this period.
- Growth and Stabilization (Mar 31, 2023 – Sep 29, 2023)
- A noticeable increase in the ratio is evident, peaking at 6.04 in the quarter ending September 29, 2023. This indicates a more efficient use of credit terms with suppliers or a decrease in accounts payable relative to cost of sales. Following this peak, the ratio stabilizes around the 5.5 to 5.8 range.
- Recent Trend (Dec 31, 2023 – Dec 31, 2025)
- A slight downward trend is observed in the most recent periods. The ratio declines from 5.52 to 5.45 by the end of the observation period. While the decline is not substantial, it warrants monitoring to determine if it represents a shift in payment practices or a change in the relationship between cost of sales and accounts payable. The ratio remains within the historical range, however.
- Overall Observations
- Throughout the analyzed period, the payables turnover ratio consistently remains above 5.0. This suggests effective management of supplier credit and a relatively quick payment cycle. The fluctuations observed are moderate and do not indicate any significant concerns regarding liquidity or supplier relationships. The recent slight decline should be monitored for potential implications.
Working Capital Turnover
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||
| Working capital | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Working capital turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits considerable fluctuation over the observed period. Initially, the ratio demonstrates a declining trend from 5.91 to 4.20 between April 2022 and December 2022. This suggests a decreasing efficiency in utilizing working capital to generate sales during this timeframe. A subsequent increase to 8.85 is observed by December 2024, indicating improved efficiency. However, the ratio then declines again to 4.13 by December 2025.
- Initial Decline (Apr 2022 - Dec 2022)
- The working capital turnover ratio decreased from 5.91 to 4.20. This decline could be attributed to an increase in working capital outpacing sales growth, or a decrease in sales relative to working capital. The largest single decrease occurred between September 2022 and December 2022.
- Significant Increase (Dec 2022 - Dec 2024)
- A substantial increase in the ratio is evident, rising from 4.22 in December 2022 to a peak of 8.85 in December 2024. This improvement suggests a more effective management of working capital, potentially through optimized inventory control, faster collection of receivables, or efficient management of payables. The most significant gains occurred between March 2023 and December 2024.
- Recent Decline (Dec 2024 - Dec 2025)
- The ratio decreased from 8.85 in December 2024 to 4.13 in December 2025. This recent decline warrants further investigation to determine the underlying causes. Potential factors include a build-up in working capital, a slowdown in sales, or a combination of both. The decrease from September 2024 to December 2025 is particularly noticeable.
- Correlation with Sales and Working Capital
- The fluctuations in the working capital turnover ratio appear to correlate with changes in both sales and working capital levels. Periods of increasing turnover generally coincide with periods where sales growth exceeds the growth in working capital. Conversely, decreasing turnover often accompanies increases in working capital relative to sales.
Overall, the working capital turnover ratio demonstrates a cyclical pattern with periods of improvement followed by declines. The recent decline from the peak in December 2024 requires attention to understand the drivers and implement strategies to improve efficiency.
Average Inventory Processing Period
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibited fluctuations over the observed timeframe. Initially, the period increased from 94 days on April 1, 2022, to 98 days on July 1, 2022, before decreasing to 91 days by December 31, 2022. A subsequent increase was noted in the first half of 2023, peaking at 104 days on March 31, 2023, and remaining elevated at 102 days on June 30, 2023.
- Inventory Processing Period Trend
- Following the peak in the first half of 2023, the average inventory processing period generally decreased, reaching 88 days by December 31, 2024. This represents the lowest point in the observed period. A slight increase occurred in the first half of 2025, rising to 99 days on September 26, 2025, before concluding at 90 days on December 31, 2025.
The period demonstrated a cyclical pattern, with increases followed by decreases. The most significant decrease occurred between September 29, 2023 (104 days) and December 31, 2024 (88 days). The period remained relatively stable between 96 and 104 days for much of 2022 and 2023. The final observed period indicates a return towards the lower end of the range, suggesting potential improvements in inventory management efficiency.
- Relationship to Inventory Turnover
- The average inventory processing period demonstrates an inverse relationship with the inventory turnover ratio. As inventory turnover increased, the processing period generally decreased, and vice versa. For example, the increase in inventory turnover from 3.80 in September 2022 to 4.03 in December 2022 coincided with a decrease in the processing period from 96 to 91 days. This correlation suggests that changes in sales and inventory management practices are impacting both metrics.
Overall, the average inventory processing period has shown a degree of volatility, but a general trend towards optimization is apparent in the later periods analyzed. Continued monitoring of this metric, alongside inventory turnover, is recommended to assess the effectiveness of inventory management strategies.
Average Receivable Collection Period
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited a generally stable pattern over the analyzed period, with fluctuations primarily occurring between the mid-50s and low-60s. An initial increase was observed from 53 days on April 1, 2022, to 54 days on July 1, 2022, followed by a slight decrease to 51 days on September 30, 2022.
A subsequent increase brought the collection period to 57 days by December 31, 2022, before stabilizing around 53-55 days through the first half of 2023. A gradual upward trend then emerged, peaking at 60 days on December 31, 2023. This was followed by a decrease to 52 days on March 29, 2024, and a period of relative stability around 54 days through December 31, 2024.
The collection period experienced a slight increase to 56 days by September 26, 2025, and concluded the analyzed period at 58 days on December 31, 2025. Overall, the fluctuations appear to be within a manageable range, though the latter portion of the period suggests a potential, albeit modest, lengthening of the collection cycle.
- Average Receivable Collection Period - Trend Analysis
- The period generally remained within a 51-60 day range. The most pronounced movement was the increase from 51 days in September 2022 to 60 days in December 2023, representing a 9-day increase over five quarters. The period then decreased to 52 days in March 2024, indicating a potential reversal of the prior trend. The final two measurements show a slight increase, but remain within the historical range.
- Average Receivable Collection Period - Volatility
- The standard deviation of the collection period over the analyzed timeframe is approximately 3.6 days, suggesting a moderate level of volatility. The largest single-quarter change occurred between September 30, 2022 (51 days) and December 31, 2022 (57 days), a 6-day increase.
- Average Receivable Collection Period - Recent Performance
- The collection period has shown a slight upward trend in the most recent quarters, moving from 54 days on December 31, 2024, to 58 days on December 31, 2025. This warrants continued monitoring to determine if this represents a sustained shift or a temporary fluctuation.
Operating Cycle
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibits fluctuations over the observed period, generally remaining within a range of 142 to 163 days. Analysis reveals trends in both the components contributing to the cycle – average inventory processing period and average receivable collection period – and their combined effect.
- Average Inventory Processing Period
- The average inventory processing period demonstrates variability, beginning at 94 days and peaking at 104 days on two occasions (September 30, 2022 and September 29, 2023). A slight downward trend is apparent in the latter half of the period, with the period concluding at 90 days in December 2025. The period generally fluctuates between 91 and 104 days, suggesting consistent, though not optimized, inventory management practices. There is a noticeable increase from 91 days in December 2022 to 104 days in September 2023, followed by a gradual decrease.
- Average Receivable Collection Period
- The average receivable collection period shows a generally increasing trend throughout the analyzed timeframe. Starting at 53 days, it consistently rises, reaching 60 days in December 2022 and continuing to 58 days by December 2025. While fluctuations occur, the overall direction indicates a lengthening of the time required to collect receivables. The period remains relatively stable between 53 and 57 days in the earlier quarters, but demonstrates a more pronounced increase in the later quarters.
- Operating Cycle
- The operating cycle initially increased from 147 days to 152 days, then remained relatively stable around 147-157 days for several quarters. A peak of 163 days was observed in September 2023, coinciding with peaks in both inventory processing and receivable collection periods. The cycle then decreased to 148 days by December 2025. The overall trend suggests a slight lengthening of the operating cycle, driven primarily by the increasing receivable collection period. The combined effect of the inventory and receivable periods results in a cycle that is sensitive to changes in either component.
The observed trends suggest a potential need to evaluate both inventory management and credit policies. While inventory processing remains relatively consistent, the increasing receivable collection period warrants further investigation to identify potential inefficiencies or changes in customer payment behavior. Monitoring these ratios closely will be crucial for maintaining optimal working capital management.
Average Payables Payment Period
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period for the analyzed period demonstrates relative stability with some fluctuation. Overall, the period generally remains within a narrow range, suggesting consistent management of supplier credit terms.
- Overall Trend
- The average payables payment period fluctuated between 60 and 73 days throughout the observed timeframe. A slight decreasing trend is discernible from the beginning of the period (72 days in Apr 1, 2022) to the middle (reaching a low of 60 days in Jun 28, 2024), followed by a slight increase towards the end of the period (67 days in Dec 31, 2025). The variations appear to be moderate and do not indicate significant shifts in payment practices.
- Short-Term Fluctuations
- An initial increase from 72 days to 73 days occurred between Apr 1, 2022, and Jul 1, 2022. Subsequently, a notable decrease to 65 days was observed by Sep 30, 2022. The period then remained relatively stable around 63-67 days for the next six quarters, before decreasing to 60 days in Jun 28, 2024. A slight increase to 66 days was seen in Dec 31, 2024, followed by a return to 63 days in Sep 26, 2025, and a final increase to 67 days in Dec 31, 2025.
- Recent Performance
- The most recent quarters show a slight upward trend, moving from 63 days in Sep 26, 2025, to 67 days in Dec 31, 2025. This suggests a potential, albeit small, lengthening of the time taken to settle payables towards the end of the analyzed period. Further monitoring is recommended to determine if this represents a sustained change.
The consistency in the average payables payment period suggests effective cash management and a stable relationship with suppliers. The minor fluctuations observed are likely attributable to normal business variations in invoice timing and volume.
Cash Conversion Cycle
| Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity, as measured by the cash conversion cycle and its components, exhibits fluctuations over the observed period. Generally, the cycle lengthened through the first half of 2023 before showing signs of contraction. A review of the individual components reveals varying trends contributing to the overall cash conversion cycle behavior.
- Average Inventory Processing Period
- The average time to process inventory generally remained within a relatively narrow range, fluctuating between 91 and 104 days. An initial increase from 94 days in April 2022 to 98 days in July 2022 was followed by a slight decrease to 91 days by December 2022. The period then increased to 104 days in March 2023, remaining elevated through September 2023. A decrease to 88 days was observed in December 2023, followed by a return to the 90-101 day range through June 2025, concluding at 90 days.
- Average Receivable Collection Period
- The average receivable collection period demonstrated a consistent upward trend from 53 days in April 2022 to 60 days in December 2022. This trend continued into the first half of 2023, peaking at 60 days in June 2023. A slight decrease to 52 days was noted in March 2024, but the period generally remained in the 54-59 day range through December 2025, ending at 58 days.
- Average Payables Payment Period
- The average payables payment period exhibited more stability than the other two components. It fluctuated between 60 and 73 days throughout the period. A slight decrease from 72 days in April 2022 to 65 days in September 2022 was followed by a period of relative stability around 65-67 days. A decrease to 60 days was observed in June 2024, with the period concluding at 67 days in December 2025.
- Cash Conversion Cycle
- The cash conversion cycle increased from 75 days in April 2022 to a peak of 98 days in September 2023. This increase was driven by increases in both the receivable collection period and the inventory processing period. A subsequent decrease to 76 days in December 2023 was observed, followed by fluctuations between 81 and 95 days through September 2024. The cycle concluded at 81 days in December 2025, representing a decrease from the peak but remaining above the initial value observed in April 2022.
The lengthening of the cash conversion cycle through 2023 suggests a potential slowdown in working capital efficiency. The subsequent partial recovery in late 2023 and 2024 indicates some improvement, but the cycle remains sensitive to changes in inventory management and collection practices. Continued monitoring of these trends is recommended.